[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594424":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":57,"collaborators":59,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":20,"eligibilityCriteria":67,"healthyVolunteers":64,"sex":68,"minAge":69,"maxAge":20,"enrollmentInfo":70,"targetDuration":20,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":81,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Yale University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Light Therapy","EXPERIMENTAL","Week 1 will include a baseline evaluation in clinic. In weeks 1-6, participants will complete 18 total light therapy sessions (3 sessions\u002Fweek, 15\u002Fminutes session). The first session will be observed in clinic at the time of the baseline evaluation, and the remaining 17 sessions will be completed at home. In Week 7 survivors will follow-up in clinic for a repeat evaluation with the physical therapist (or study team member). .",[13],"Device: Anodyne Therapy System",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Anodyne Therapy System","Survivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Rozalyn Rodwin, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","203-785-2407","rozalyn.rodwin@yale.edu",{"name":31,"role":27,"phone":28,"phoneExt":20,"email":32},"Jaime Rotatori, BSN, MS","jaime.rotatori@yale.edu",[34,48],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":20},"Yale New Haven Health Smilow York Street Hospital","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-72.92816,41.30815,{"lat":46,"lon":45},{"facility":49,"status":36,"city":50,"state":38,"zip":51,"country":40,"countryCode":41,"cosmosGeoPoint":52,"geoPoint":56,"contacts":20},"Yale New Haven Health Park Avenue Medical Center","Trumbull","06611",{"type":43,"coordinates":53},[54,55],-73.20067,41.24287,{"lat":55,"lon":54},{"type":58,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[60],{"name":61,"class":6},"Rally Foundation for Childhood Cancer Research","100594424","light-therapy-for-chemotherapy-induced-peripheral-neuropathy-in-childhood-cancer-survivors-100594424",false,"NCT07019259","Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors","Inclusion Criteria:\n\n* History of childhood cancer (\\\u003C21 years of age at diagnosis)\n* Current age five years or older (due to availability of validated measures for CIPN in this age group)\n* History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN\n* CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \\\u003C18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)\n\nExclusion Criteria:\n\n* Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)\n* Inability to sit still for at least 15 minutes\n* Diagnosis of neuropathy prior to cancer treatment\n* Active cancer diagnosis or cancerous skin lesion\n* Central nervous system tumor (due to lack of validated measures for CIPN in this population)\n* Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.","ALL","5 Years",{"count":71,"type":72},20,"ESTIMATED","INTERVENTIONAL",[75],"NA","The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.",[78,79,80],"Cancer","Childhood Cancer","Chemotherapy-induced Peripheral Neuropathy",[82],"Survivors of childhood cancer","2026-06-11",{"date":85,"type":86},"2026-06-12","ACTUAL",{"date":88,"type":86},"2025-06-30",{"date":90,"type":72},"2027-04",{"name":5,"class":6},2]